PERLANE approved for sales in the USA

The U.S. Food and Drug Administration (“FDA”) has approved PERLANE for sales in the USA.

FDA’s approval of PERLANE means that Q-Med will receive the final purchase sum from the agreement 2003 of USD 29.1 million from the American company Medicis, which holds the rights to sell and market PERLANE in the USA and Canada. Q-Med is the exclusive manufacturer of the product. Medicis anticipates that it will be able to begin selling PERLANE in the USA within 30 days.

PERLANE consists of a crystal-clear gel that is injected into the skin for the filling out of deeper folds and wrinkles and for the treatment of lips. In the USA the approval only comprises the filling out of folds and wrinkles. The product is based on Q-Med’s patented technology, NASHA, for the production of stabilized, non-animal hyaluronic acid and has been approved in Europe since the year 2000.

Medicis is a leading specialty pharmaceutical company in the USA within dermatology that offers products for, amongst other things, the treatment of acne, asthma, hyperpigmentation, psoriasis, eczema, skin infections and a large number of other skin-related conditions. Medicis is listed on NYSE (MRX).